The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence

Journal of Autoimmunity

Volumn 32, Issue 1, 2009, Pages 1-6

  Ortega Hernandez, Oscar Danilo ^a   Agmon Levin, Nancy ^a   Blank, Miri ^a,b   Asherson, Ronald A ^b,c   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiphospholipid antibodies; Catastrophic antiphospholipid syndrome; DIC; HIT; Infection; Microthromboses; Molecular mimicry; SIRS; TTP

Indexed keywords

CROSS REACTING ANTIBODY;

ANEMIA; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISASTER; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; MICROVASCULATURE; MOLECULAR MIMICRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA;

ANEMIA, HEMOLYTIC; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIAL CELLS; HUMANS; INFECTION; MODELS, BIOLOGICAL; MOLECULAR MIMICRY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 58849102082     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.10.003     Document Type: Review

References (60)

1. Asherson R.A. The catastrophic antiphospholipid syndrome. J Rheumatol 19 (1992) 508-512
2. Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 (1998) 195-207
3. Asherson R.A. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 7 (1998) S55-S62
4. Asherson R.A., Cervera R., de Groot P.G., Erkan D., Boffa M.C., Piette J.C., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
5. Meroni P.L., and Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 7 (2008) 585-587
6. Cervera R., and Asherton R.A. Catastrophic antiphospholipid syndrome. Pathophysiol Haemost Thromb 35 (2006) 181-186
7. Asherson R.A., and Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome. Molecular mimicry?. J Rheumatol 27 (2000) 12-14
8. Koike T., Bohgaki M., Amengual O., and Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28 (2007) 129-133
9. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 30 (2008) 99-103
10. Sodin-Semrl S., and Rozman B. Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels. Autoimmun Rev 6 (2007) 547-552
11. Espinosa G., Bucciarelli S., Cervera R., Gómez-Puerta J.A., and Font J. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev 6 (2006) 68-71
12. Kitchens C.S. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104 (1998) 381-385
13. Meroni P.L., Raschi E., Camera M., Testoni C., Nicoletti F., Tincani A., et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 15 (2000) 237-240
14. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101 (2003) 3495-3500
15. Vega-Ostertag M.E., and Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 9 (2007) 190-197
16. Gharavi A.E., and Pierangeli S.S. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus 7 (1998) S52-S54
17. Cavazzana I., Manuela N., Irene C., Barbara A., Sara S., Orietta B.M., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 28 (2007) 160-164
18. Gharavi E.E., Chaimovich H., Cucurull E., Celli C.M., Tang H., Wilson W.A., et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 8 (1999) 449-455
19. Kajiwara T., Yasuda T., and Matsuura E. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 29 (2007) 164-173
20. Sherer Y., Blank M., and Shoenfeld Y. Antiphospholipid syndrome (APS): where does it come from?. Best Pract Res Clin Rheumatol 21 (2007) 1071-1078
21. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., and Kruithof E.K. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 88 (2002) 851-857
22. Arfors L., Vesterqvist O., Johnsson H., and Gréen K. Increased thromboxane formation in patients with antiphospholipid syndrome. Eur J Clin Invest 20 (1990) 607-612
23. Del Papa N., Guidali L., Sala A., Buccellati C., Khamashta M.A., Ichikawa K., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40 (1997) 551-561
24. Meroni P.L., Ronda N., De Angelis V., Grossi C., Raschi E., and Borghi M.O. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. Clin Rev Allergy Immunol 32 (2007) 67-74
25. Blank M., Asherson R.A., Cervera R., and Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol 24 (2004) 12-23
26. Atkinson T.J. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness?. Int Rev Immunol 27 (2008) 255-281
27. Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X., Colden-Stanfield M., and Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 46 (2002) 545-552
28. Meroni P.L., Raschi E., Testoni C., Tincani A., Balestrieri G., Molteni R., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44 (2001) 2870-2878
29. Tincani A., Spatola L., Prati E., Allegri F., Ferremi P., Cattaneo R., et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 157 (1996) 5732-5738
30. Vora S.K., Asherson R.A., and Erkan D. Catastrophic antiphospholipid syndrome. J Intensive Care Med 21 (2006) 144-159
31. Sène D., Piette J.C., and Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 7 (2008) 272-277
32. Cervera R. Lessons from the "Euro-Phospholipid" project. Autoimmun Rev 7 (2008) 174-178
33. Cervera R., Espinosa G., Bucciarelli S., Gómez-Puerta J.A., and Font J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev 6 (2006) 81-84
34. Gharavi A.E., Pierangeli S.S., Colden-Stanfield M., Liu X.W., Espinola R.G., and Harris E.N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 163 (1999) 2922-2927
35. Asherson R.A. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 210 (2005) 727-733
36. Espinosa G., Cervera R., and Asherson R.A. Catastrophic antiphospholipid syndrome and sepsis. A common link?. J Rheumatol 34 (2007) 923-926
37. Dunoyer-Geindre S., Boehlen F., Favier R., Wahl D., Musial J., Korte W., et al. Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome. Haematologica 93 (2008) 635-636
38. Pierangeli S.S., Espinola R.G., Liu X., and Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 88 (2001) 245-250
39. Asherson R.A., Cervera R., and Shoenfeld Y. Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann N Y Acad Sci 1108 (2007) 515-529
40. Hamid C., Norgate K., D'Cruz D.P., Khamashta M.A., Arno M., Pearson J.D., et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 66 (2007) 1000-1007
41. Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J.A., Ramos-Casals M., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54 (2006) 2568-2576
42. Dalainas I. Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. Eur Rev Med Pharmacol Sci 12 (2008) 19-31
43. Bick R.L., Arun B., and Frenkel E.P. Disseminated intravascular coagulation. Clinical and physiopathological mechanisms and manifestations. Haemostasis 29 (1999) 111-134
44. Gómez-Puerta J.A., Cervera R., Espinosa G., Bucciarelli S., and Font J. Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. Autoimmun Rev 6 (2006) 85-88
45. Makatsariya A., Asherson R.A., Bitsadze V., Baimuradova S., and Akinshina S. Catastrophic antiphospholipid (Asherson's) syndrome and genetic thrombophilic disorders in obstetrics. Autoimmun Rev 6 (2006) 89-93
46. Miesbach W., Asherson R.A., Cervera R., Shoenfeld Y., Gomez Puerta J., Bucciarelli S., et al. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev 6 (2006) 94-97
47. Nakamura N., Shidara Y., Kawaguchi N., Azuma C., Mitsuda N., Onishi S., et al. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun 205 (1994) 1488-1493
48. Mitra D., Kim J., MacLow C., Karsan A., and Laurence J. Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Am J Hematol 59 (1998) 279-287
49. Franchini M. Thrombotic microangiopathies: an update. Hematology 11 (2006) 139-146
50. Gómez-Puerta J.A., Cervera R., Espinosa G., Asherson R.A., García-Carrasco M., da Costa I.P., et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 66 (2007) 740-746
51. Kravitz M.S., and Shoenfeld Y. Thrombocytopenic conditions - autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol 80 (2005) 232-242
52. Hurlimann-Forster M., Steiner B., and von Felten A. Quantitation of platelet-specific autoantibodies in platelet eluates of ITP patients measured by a novel ELISA using the purified glycoprotein complexes GPIIb/IIIa and GPIb/IX as antigens. Br J Haematol 98 (1997) 328-335
53. Triplett D.A., and Asherson R.A. Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 66 (2000) 154-159
54. Pabinger I., and Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 16 (1996) 742-748
55. Lai S., Walker D.H., and Elghetany M.T. Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury - a case report with pathological and molecular correlative studies. Pathol Int 55 (2005) 144-149
56. Yasuda S., Atsumi T., Matsuura E., Kaihara K., Yamamoto D., Ichikawa K., et al. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum 52 (2005) 212-218
57. Blank M., Anafi L., Zandman-Goddard G., Krause I., Goldman S., Shalev E., et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 19 (2007) 857-865
58. Blank M., Shoenfeld Y., Cabilly S., Heldman Y., Fridkin M., and Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 96 (1999) 5164-5168
59. Bagnasco M., Grassia L., and Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 6 (2007) 347-353
60. Cheng H.M., and Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun Rev 7 (2008) 431-434